LEXAPRO Drug Profile, 2019 - Patents, Clinical Trials, Drug Prices, Annual Sales Revenues and Raw API Sources - ResearchAndMarkets.com

The "LEXAPRO Drug Profile, 2019" report has been added to ResearchAndMarkets.com's offering.

LEXAPRO Drug Profile, 2019 is part of a deep library of business intelligence on biopharmaceutical drugs. The report focuses on LEXAPRO and covers the following critical aspects of this drug:

• United States patents
• Expired United States patents
• FDA Paragraph IV patent challenges
• District Court patent litigation
• European supplementary protection certificates (SPCs)
• Clinical trials
• Drug prices
• Annual sales revenues
• Finished product suppliers
• Raw active pharmaceutical ingredient (API) sources

Topics Covered

• Profile for LEXAPRO
• US Patents
• Expired US Patents
• Paragraph IV Patent Challenges
• US District Court Litigation
• International (ex US) Patents
• Supplementary Protection Certificates
• Clinical Trials
• Drug Prices - Average Pharmacy Cost
• Drug Prices - Best Wholesale Price
• Annual Sales Revenues
• Finished Product Suppliers
• Bulk API Sources

Companies Featured

• Allergan Inc.
• Mylan Institutional Inc.
• Blenheim Pharmacal Inc.
• Bryant Ranch Prepack
• Novoseek
• Molport
• Abi Chem
• Chemmol
• Chembase.Cn
• Acesobio
• Ak Scientific Inc. (Aksci)
• Tractus
• Abachemscene
• Medchemexpress Mce
• Wolves R&D Chemical
• A&J Pharmtech Co. Ltd.
• An Pharmatech
• Syntree
• Tocris Bioscience
• Oxchem Corporation
• Targetmol
• Boc Sciences
• Phion Ltd
• Apexbio Technology
• Labseeker
• Yuhao Chemical
• LGC Standards
• Dc Chemicals
• Ochem
• Labnetwork
• Ambinter
• Bld Pharm
• Biochempartner
• Hairui Chemical
• and many more...
  

For more information about this report visit https://www.researchandmarkets.com/research/h3vfcv/lexapro_drug?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20190114005407/en/